Dicerna Pharma (DRNA) Reports Q1 Loss of $0.38/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dicerna™ Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update
May 9, 2019 4:05 PM EDTInitiated Screening of Participants to Enroll in the PHYOX2 Phase 2 Pivotal Trial of DCR-PHXC for the Treatment of Primary Hyperoxaluria (PH) and Announced Updated Data from Ongoing PHYOX1 Phase 1 of DCR-PHXC
Dosed First Healthy Volunteer in Phase 1 Clinical Trial of DCR-HBVS for Treatment of Chronic Hepatitis B Virus (HBV) Infection
Advanced Boehringer Ingelheim Collaboration with Exercise of Option for Second Hepatic Disease Target for Non-Alcoholic Steatohepatitis (NASH) and Other Chronic Liver Diseases
Management to Host Conference Call Today at 4:30 p.m. ETÂ
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
